This profile was last updated on //
Is this you? Claim your profile.
210 Broadway Suite 201
CureVac is an integrated biopharmaceutical company with a pipeline of promising drug candidates. Using its RNA technology platform, CureVac is currently developing therapeutic mRNA vaccines (RNActive®) and vaccine adjuvants, comprised of long, non-coding
Find other employees at this company (73)
(151 Total References)
In the late 1990s, Dr. Ingmar Hoerr, Co-founder and CEO of CureVac, made an unexpected discovery during his doctoral research in biology, which was contrary to the established scientific belief at the time: RNA, which was generally thought to be a very unstable biomolecule, could be administered directly into tissue as a therapeutic vaccine or agent once the biological properties of the molecule were appropriately modified.
Furthermore, complicated formulations or molecular packaging were not required to achieve these results.
This discovery led to a new fundamental understanding of the potential of RNA to treat diseases and to generate prophylactic immunity.
These fascinating possibilities prompted the company's three founders, Ingmar Hoerr, Steve Pascolo and Florian von der Mülbe, to found CureVac without investors during the difficult market environment of 2000.
Dr. Ingmar Hoerr, CEO of ...
Dr. Ingmar Hoerr, CEO of CureVac, said "I believe these new results are excellent news for patients.
Ingmar Hoerr, PhD, ...
Ingmar Hoerr, PhD, MBA
Chairman / Chief Executive Officer
From this key discovery, Ingmar Hoerr
and Florian von der Mülbe built up a company that is now a global leader in the research and development of mRNA-based drugs.
Ingmar Hoerr received his PhD from the University of Tübingen and his MBA from Danube University, Krems, Austria.
Florian worked with Biotest GmbH and Roche AG before joining CureVac in 2000 - working with Ingmar Hoerr to build the business from the start.
Ingmar Hoerr, PhD, ...
Ingmar Hoerr, PhD, co-founder and CEO of CureVac, said, "We are delighted to welcome these esteemed experts to CureVac's Scientific Advisory Board during this time of significant growth and progress for CureVac.
Ingmar Hoerr, Ph.D., ...
Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, stated, "We are pleased to welcome these highly-respected experts to CureVac's supervisory board as we continue to advance our mRNA-based medicines to address significant therapeutic needs and global market opportunities."